Alan D. Sobel

This profile gathers the share dealings of Alan D. Sobel in Cytosorbents Corp, where the filings describe the role as board member. In total, 15 filings cover trades dated from 8 April 2015 to 15 September 2026.

Every open-market trade on record is a purchase: 6 purchases worth €60k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 5 share grants. 2026 to date brings 3 purchases and no sales.

Half of the purchases are above €6,348 and half below. Scaled by market value, the purchases weigh a median 0.019% of market cap (sample: 3 purchases). Clusters matter here: 6 out of 6 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 16 September 2026 came the latest disclosure, an open-market purchase for €521 in Cytosorbents Corp. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.